JP Morgan Chase
MDGL icon

JP Morgan Chase’s Madrigal Pharmaceuticals MDGL Stock Holding History

JP Morgan Chase’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-22,600
Closed -$6.97M – 7576
2024
Q4 		$6.97M Sell
22,600
-15,900
-41% -$4.47M ﹤0.01% 3043
2024
Q3 		$8.17M Sell
38,500
-4,100
-10% -$1.05M ﹤0.01% 2779
2024
Q2 		$11.9M Sell
42,600
-17,600
-29% -$4.19M ﹤0.01% 2297
2024
Q1 		$16.1M Buy
60,200
+13,700
+29% +$3.23M ﹤0.01% 2070
2023
Q4 		$10.8M Sell
46,500
-27,000
-37% -$4.72M ﹤0.01% 2397
2023
Q3 		$10.7M Sell
73,500
-345,100
-82% -$65M ﹤0.01% 2186
2023
Q2 		$96.7M Sell
418,600
-2,700
-0.6% -$731K 0.01% 840
2023
Q1 		$102M Buy
421,300
+411,300
+4,113% +$112M 0.01% 786
2022
Q4 		$2.9M Buy
+10,000
New +$978K ﹤0.01% 3267
2019
Q2 		– Sell
-27,000
Closed -$3.38M – 5901
2019
Q1 		$3.38M Buy
27,000
+18,000
+200% +$2.24M ﹤0.01% 2918
2018
Q4 		$1.01M Buy
+9,000
New +$1.39M ﹤0.01% 3743

Other funds holding MDGL

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase's MDGL Position: Q1 2026 in Review

JP Morgan Chase reduced its Madrigal Pharmaceuticals (MDGL) stake by 9.4% in Q1 2026, selling an estimated $1.8M and leaving 36,315 shares worth $18.4M. The position accounts for ﹤0.01% of the portfolio, ranked #2149.

JP Morgan Chase first reported a position in MDGL in Q2 2013 and has held it in 41 quarters since. The position peaked at $44M in Q4 2018. 378 funds tracked by Wall St. Rank hold MDGL as of Q1 2026.

  • JP Morgan Chase held 36,315 shares of Madrigal Pharmaceuticals worth $18.4M as of Q1 2026.
  • JP Morgan Chase sold 3,764 Madrigal Pharmaceuticals shares in Q1 2026, an estimated $1.8M.
  • Madrigal Pharmaceuticals made up ﹤0.01% of JP Morgan Chase's portfolio in Q1 2026, its #2149 holding.
  • JP Morgan Chase first reported a position in Madrigal Pharmaceuticals in Q2 2013 and has held it in 41 quarters since.
  • JP Morgan Chase's Madrigal Pharmaceuticals position peaked at $44M in Q4 2018.
  • 378 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.